Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids

Pain Practice

Volumn 12, Issue 1, 2012, Pages 45-56

  Pergolizzi, Joseph V ^a,b,c   Labhsetwar, Sumedha A ^c   Amy Puenpatom, R ^d   Ben Joseph, Rami ^d   Ohsfeldt, Robert ^e   Summers, Kent H ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEMA Research   (United States)

^d Endo Pharmaceuticals   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Analgesics; Back pain; Low back pain; Lower back pain; Narcotics; Opioid; Opioid analgesics; Pharmacologic actions; Therapeutics

Indexed keywords

CODEINE; CYTOCHROME P450; FENTANYL; HYDROCODONE; METHADONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TRAMADOL;

ADULT; AGED; ARTICLE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

EID: 84855728472     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00503.x     Document Type: Article

References (43)

1. Kent P, Keating J. The epidemiology f low back pain in primary care. Chiropr Osteopat. 2005;13:13-20.
2. Chronic Low-Back Pain On The Rise: Study Finds 'Alarming Increase' In Prevalence. North Carolonia: University of North Carolina School of Medicine; 2009, [cited 2010 July 28]; Available from:
3. Freburger J, Holmes G, Agans R, et al. The rising prevalence of chronic low back pain. Arch Intern Med. 2009;169:251-258.
4. Hoy D, March L, Brooks P, et al. Measuring the global burden of low back pain. Best Pract Res Clin Rheumatol. 2010;24:155-165.
5. VanTulder M, Koes B, Bombardier C. Low back pain. Best Pract Res Clin Rheumatol. 2002;16:761-775.
6. Knauer S, Freburger J, Carey T. Chronic low back pain among older adults: a population-based perspective. J Aging Health. 2010;22:1213-1234.
7. Martin B, Deyo R, Mirza S, et al. Expenditures and health status among adults with back and neck problems. JAMA. 2008;299:656-664.
8. Nimgade A, McNeely E, Milton D, Celona J. Increased expenditures for other health conditions after an incident of low back pain. Spine (Phila Pa 1976). 2010;35:769-777.
9. Mortimer M, Ahlberg G. To seek or not to seek? Care-seeking behaviour among people with low-back pain. Scand J Public Health. 2003;31:194-203.
10. Chou R. Pharmacological management of low back pain. Drugs. 2010;70:387-402.
11. Chou R, Qaseem A, Snow V, Cross JT Jr., Shekelle P, Owens DK. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147:478-491.
12. Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med. 2009;10:S20-S29.
13. Pergolizzi J, Labhsetwar S, Puenpatom R, Joo S, Ben-Joseph R, Summers K. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 2011;11:230-239.
14. Pergolizzi J, Labhsetwar S, Puenpatom R, Joo S, Ben-Joseph R, Summers K. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract. 2011;11:325-336.
15. Grymonpre R, Sitar D. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc. 1988;36:1092-1098.
16. Jankel C, McMillan J, Marin B. Effect of drug ineractions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm. 1994;51:661-666.
17. Goldberg R, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447-450.
18. Einarson T, Metge C, Iskedjian M, Mukherjee J. An examination of the effect of cytocrhome P450 drug interactions on hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126-2136.
19. Juurlink D, Mamdani M, Kopp A, Laupacis A, Redelmeier D. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658.
20. Classen D, Jaser L, Budnitz D. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 2010;36:12-21.
21. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol. 2007;25:7-9.
22. Kaushal R, Bates D, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285:2114-2120.
23. Malone D, Hutchins D, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm. 2005;62:1983-1991.
24. Sandson N. Drug-drug interactions: the silent epidemic. Psychiatr Serv. 2005;56:22-25.
25. Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged =>55years. Drugs Aging. 2008;25:145-152.
26. Huang S, Lesko L, Williams R. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol. 1999;39:1006-1014.
27. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61:515-520.
28. Mahmood M, Malone D, Skrepnek G, et al. Potential drug-drug interactions with Veterans Affairs medical centers. Am J Health Syst Pharm. 2007;64:1500-1505.
29. Haijar E, Hanlon J, Artz M, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother. 2003;1:82-89.
30. Nguyen J, Fouts M, Kotabe S, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4:36-41.
31. Gurwitz J, Field T, Harrold L, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
32. Kurz A, Sessler D. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs Aging. 2003;63:649-671.
33. Pappagallo M. Incidence, prevalence, and managment of opioid bowel dysfunction. Am J Surg. 2001;185(5A suppl):11S-18S.
34. Hale M, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2007;8:175-184.
35. Hohl C, Abu-Laban R, Zed P, et al. Patient-reported adverse drug-related events from emergency department discharge prescriptions. CJEM. 2010;12:331-338.
36. D'Agostino J. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
37. Rascati K, Smith M, Neilands T. Dealing with skewed data: an example using asthma-related costs for Medicaid clients. Clin Ther. 2001;23:481-498.
38. Barnett V, Lewis T. Outliers in Statistical Data, 3rd ed. West Sussex, England: Wiley; 1994.
39. Raebel M, Malone D, Conner D, Xu S, Porter J, Lanty F. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med. 2004;164:2135-2140.
40. Solberg L, Hurley J, Roberts M, et al. Measuring patient safety in ambulatory care: potential for identifying group drug-drug interaction rates using claims data. Am J Manag Care. 2005;10:753-759.
41. Peng C, Glassman P, Marks I, Fowler C, Castiglione B, Good C. Retrospective drug utilization review: incidence of clinically relevant drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2005;9:513-522.
42. Dickson M, Bramley T, Kozma C, Doshi D, Rupnow M. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health Syst Pharm. 2008;65:1983-1991.
43. Qato D, Alexander G, Conti R, Johnson M, Schumm P, Lindau S. Use of prescription and over-the-counter medications and dieatry supplements among older adults in the United States. JAMA. 2008;300:2867-2878.